超1.27万亿！南向资金加仓再创历史新高 非银、创新药、科技持续“吸金”

Core Insights - Southbound capital has been a significant source of inflow into the Hong Kong stock market, with a cumulative net inflow exceeding 1.27 trillion HKD this year, marking a historical high for annual net inflows [1] - The innovative drug, technology, and non-bank sectors have seen substantial gains, with respective year-to-date increases of 79%, 53%, and 34%, compared to a 26% rise in the Hang Seng Index [1] - The largest Hong Kong innovative drug ETF (513120) received a net inflow of 585 million HKD in a single day, bringing its total size to 23.7 billion HKD [1] Fund Flows - The total net inflow for all ETFs in the market exceeded 3.777 billion HKD, with significant inflows into non-bank financials, innovative drugs, and technology sectors [1] - GF Fund Management led all public institutions with a total net inflow of 1.997 billion HKD across its ETFs, including those focused on A-shares and other sectors [2] - Notable ETFs under GF Fund Management include the innovative drug ETF (515120), low-fee创业板 ETF (159952), and the largest media ETF (512980), each receiving over 100 million HKD in net inflows [2] Market Outlook - Market volatility has increased entering November, with industry experts suggesting that fundamental improvements in 2026 may drive further gains in the Hong Kong stock market [2] - The AI industry is expected to catalyze improvements in net asset return rates (ROE) for sectors represented by the Hang Seng Technology Index, potentially leading to higher market valuations [2] - In terms of asset allocation, while the technology sector remains favorable, innovative drugs, non-bank financials, and certain cyclical assets are also worth attention [2]